Hematotoxicity
At Vivia Biotech, hematotoxicity is evaluated using high-content ex vivo assays that preserve the native hematopoietic microenvironment, enabling physiologically relevant assessments of compound-induced cytotoxicity. Our platforms combine multiparametric flow cytometry with fixed volumetric acquisition to quantify lineage-specific effects on hematopoietic precursors. These models provide robust data on direct hematotoxicity, off-target activity, and ADC-associated myelosuppression, supporting informed decision-making throughout preclinical and translational development.
Hematopoietic Stem Cells (HSCs) are the responsible to replenish mature blood cells after hematopoietic stresses. One of the most common dose limiting adverse effects in cancer treatment is myelosuppression, which describes adverse effects on the blood forming system. Here, we provide an assay to measure depletion of different subsets of CD34+ progenitors in Normal Bone Marrow (NBM) or other hematological diseases to potentially screen drug candidates and combinations for hematotoxicity, as well as personalize therapy to the individual sensitive patient at risk.
Vivia Biotech has developed advanced ex vivo therapeutic index assays that accurately quantify the anti-tumor activity and hematotoxic effects of Antibody-Drug Conjugates (ADCs) in physiologically relevant conditions, enabling robust evaluation of their therapeutic window and mechanism of action.